Quick Answer
Denali Therapeutics Inc. reported Net Income of -$512.54 million for fiscal year 2025.
Denali Therapeutics Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$512.54M | -21.2% |
| 2024 | -$422.77M | -191.1% |
| 2023 | -$145.22M | +55.5% |
| 2022 | -$325.99M | -12.2% |
| 2021 | -$290.58M | -508.5% |
| 2020 | $71.14M | +136.0% |
| 2019 | -$197.61M | -445.3% |
| 2018 | -$36.24M | +58.9% |
| 2017 | -$88.19M | -1.8% |
| 2016 | -$86.65M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$126.90M | -18.4% | -2.2% |
| June 30, 2025 | -$124.12M | -25.3% | +6.7% |
| March 31, 2025 | -$132.97M | -30.6% | -24.0% |
| September 30, 2024 | -$107.19M | -7.9% | -8.2% |
| June 30, 2024 | -$99.03M | -154.0% | +2.7% |
| March 31, 2024 | -$101.80M | +7.3% | -2.5% |
| September 30, 2023 | -$99.35M | +3.8% | -154.2% |
| June 30, 2023 | $183.38M | +411.9% | +267.0% |
- Denali Therapeutics Inc. showed a decrease of -21.2% in Net Income compared to the prior fiscal year.
- Over the 2016–2025 period, Denali Therapeutics Inc.’s net income has declined by 491.5% (from -$86.65 million to -$512.54 million).
- The most recent figure is from Denali Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: